S100B and ovarian cancer: In vitro studies could demonstrate that S100B contributes to cisplatin resistance in ovarian cancer stem cells (OCSC) by inhibiting p53 and therefore promoting multidrug resistance gene 1 (MDR1) and MDR-associated protein 1 (MRP1) [148,149].